Widely-studied innovative formulation proven to help patients with gastrointestinal conditions manage their symptoms
ExeGi Pharma's Visbiome is now available in Canada. The high potency probiotic contains a proprietary blend of eight strains of live freeze-dried lactic acid bacteria and is available in concentrations of 450 billion colony forming units (CFUs) bacteria per sachet.
The innovative formulation (the 'De Simone Formulation') was originally invented by Professor Claudio De Simone more than 20 years ago and has been subject to extensive research in 60 studies and more than 170 scientific publications.
Visbiome delivers probiotic bacteria in high concentrations, which helps to normalise the gut flora in pouchitis patients; it is also used to reduce the risk of relapse in pouchitis. In conjunction with mesalamine, it can also help reduce the Ulcerative Colitis Disease Activity Index (UCDAI) by half within six weeks in patients with mild to moderate active ulcerative colitis.
Visbiome is currently undergoing additional clinical studies in a variety of conditions, including two large trials designed to evaluate Visbiome's potential in reducing damaging systemic inflammation of HIV positive patients. One of these studies is funded by the Ontario HIV Treatment Network and the Canadian Institutes of Health Research (CIHR) Canadian HIV Trials Network and is currently recruiting patients in two sites in Toronto.
'Visbiome has a proven track record of helping patients successfully treat and manage challenging gastroenterological conditions,' said Marc Tewey, CEO of ExeGi Pharma. 'Now that Visbiome is available to patients in Canada, healthcare professionals have an important new tool to help their patients stabilise their conditions.'